Company intelligence / Profile preview

Symbiosis Pharma

Stirling, Scotland, United Kingdom

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Symbiosis Pharmaceutical Services is a specialized Contract Development and Manufacturing Organization (CDMO) focused on sterile fill-finish services for biologics and small molecules. Based in Stirling, Scotland, the company supports biotechnology and pharmaceutical clients globally through clinical trial supply and commercial-scale manufacturing. Their expertise includes handling complex products such as viral vectors, vaccines, and highly potent compounds. Symbiosis is recognized for its rapid turnaround times and flexible manufacturing solutions tailored to the needs of emerging biotech firms and global pharmaceutical companies alike.

Modalities: BiologicSmall moleculeVaccineViral vector therapyMonoclonal antibodymRNA-based drugsPeptidesCytotoxic drugs
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Symbiosis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symbiosis Pharma.

Explore the full profile